Drug Database · Clinicians

Diltiazem

Brands (14) Diltimax, Angiozem, Dilzem…Show all

US brand (reference label): Cardizem; not a Philippine-registered brand.

Calcium channel blocker (benzothiazepine derivative); Channel blocker (benzothiazepine derivative) PH FDA category

Rx · Prescription drug21 PH productsPNF-listedPhilHealth GAMOTVAT-exempt
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
Label text on this page: US FDA-approved label via DailyMed/openFDA, set ID f3e7ecef-f360-4987-a4f5-933214130ab2, version date April 30, 2025 (Cardizem · Bausch Health US LLC). Reproduced verbatim. Philippine-approved indications and doses may differ: check the PH package insert.

Use: Labeled indications

  • INDICATIONS AND USAGE CARDIZEM is indicated for the management of chronic stable angina and angina due to coronary artery spasm.
US FDA label
Full indications and usage US FDA label

INDICATIONS AND USAGE CARDIZEM is indicated for the management of chronic stable angina and angina due to coronary artery spasm.

Contraindications

CONTRAINDICATIONS CARDIZEM is contraindicated in: Patients with sick sinus syndrome except in the presence of a functioning ventricular pacemaker Patients with second- or third-degree AV block except in the presence of a functioning ventricular pacemaker Patients with hypotension (less than 90 mm Hg systolic) Patients who have demonstrated hypersensitivity to the drug Patients with acute myocardial infarction and pulmonary congestion documented by x-ray on admission

US FDA label

Dosing: Adult

Dosage and administration (US label) US FDA label

DOSAGE AND ADMINISTRATION Exertional Angina Pectoris Due to Atherosclerotic Coronary Artery Disease or Angina Pectoris at Rest Due to Coronary Artery Spasm: Dosage must be adjusted to each patient’s needs. Starting with 30 mg four times daily, before meals and at bedtime, dosage should be increased gradually (given in divided doses three or four times daily) at 1- to 2-day intervals until optimum response is obtained.

Although individual patients may respond to any dosage level, the average optimum dosage range appears to be 180 to 360 mg/day. There are no available data concerning dosage requirements in patients with impaired renal or hepatic function. If the drug must be used in such patients, titration should be carried out with particular caution.

Concomitant Use with Other Cardiovascular Agents Sublingual NTG may be taken as required to abort acute anginal attacks during CARDIZEM (diltiazem hydrochloride) therapy. Prophylactic Nitrate Therapy. CARDIZEM may be safely coadministered with short- and long-acting nitrates, but there have been no controlled studies to evaluate the antianginal effectiveness of this combination.

Beta-blockers. (see WARNINGS and PRECAUTIONS.) 30 mg – CARDIZEM tablets may be swallowed whole, crushed, or chewed. Do not split CARDIZEM tablets. 60 mg, 90 mg, and 120 mg – CARDIZEM tablets may be swallowed whole, crushed, or chewed.

Dosing: Altered kidney function

From the US FDA label · Dosage and administration (renal excerpts)

There are no available data concerning dosage requirements in patients with impaired renal or hepatic function.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosing: Pediatric

Pediatric use (US label) US FDA label

Pediatric Use Safety and effectiveness in pediatric patients have not been established.

Dosing: Older adult

Geriatric use (US label) US FDA label

Geriatric Use Clinical studies of diltiazem did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Dosage forms

Philippines

  • Tablet: 30 mg, 60 mg, 90 mg
  • Film-coated tablet: 30 mg, 60 mg, 90 mg
  • Sustained-release tablet: 120 mg, 180 mg

Registered products in the Philippines

21 products registered with the Food and Drug Administration (FDA) Philippines list Diltiazem as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

All registered products21
Philippine FDA-registered products for Diltiazem
Package insert
AngiozemDiltiazem (as Hydrochloride)
30 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Yu Sheng Pharmaceutical Co., Ltd.Taiwan
Importer: Littman Drug Corporation
DR-XY26629
Oct 12, 2028
AngiozemDiltiazem (as Hydrochloride)
30 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Yu Sheng Pharmaceutical Co., Ltd.Taiwan
Litttman Drug Corporation
DR-XY26641
Oct 19, 2028
CorvizemDiltiazem hydrochloride
30 mg Film-Coated TabletAlu/ Clear PVC Blister Pack x 20's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
Trader: D.B. Manix International, Inc.
DRP-871
Jul 27, 2030
DiltimaxDiltiazem Hydrochloride
30mg TabletAlu-PVC Blister Pack
RxVAT-exempt
Fredun Pharmaceuticals Limited.India
AMB HK Enterprises Inc.
DRP-14806
Jan 25, 2029
DiltimaxDiltiazem hydrochloride
60mg TabletAlu/PVC blister pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-14401
Sep 8, 2028
DiltimaxDiltiazem Hydrochloride
60mg TabletAlu/PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Fredun Pharmaceuticals LimitedIndia
AMB HK Enterprises Inc.
DRP-14805
Jan 25, 2029
DilzemDiltiazem hydrochloride
30 mg TabletAlu/Clear PVC Blister Pack x 20's (Box of 200's) Alu/Clear PVC Blister Pack x 1's (Physician's sample)
RxVAT-exempt
Interphil Laboratories, Inc.Philippines
Trader: Pfizer, Inc
DRP-2100
Oct 24, 2030
DilzemDiltiazem hydrochloride
60 mg TabletAlu/Clear PVC Blister Pack x 20's (Box of 200's)
RxVAT-exempt
Interphil Laboratories, Inc.Philippines
Trader: Pfizer, Inc.
DRP-2010
Oct 8, 2029
Dilzem ODDiltiazem Hydrochloride
120 mg Sustained-Release TabletClear PVC/Alu Blister Pack x 10's (Box of 60's)
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Importer: Pfizer, Inc.
DRP-2009
Apr 16, 2029
Dilzem SADiltiazem hydrochloride
90 mg TabletBlister pack x 20's (Box of 60's)
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Importer: Pfizer, Inc.
DRP-2012
Jan 10, 2028
Dilzem SRDiltiazem Hydrochloride
180 mg Sustained-Release TabletAlu - PVC Blister Pack x 20's (Box of 60's)
RxVAT-exempt
Pfizer Manufacturing Deutschland GmbHGermany
Importer: Pfizer, Inc.
DRP-2011
Feb 1, 2030
Dilzep 60Diltiazem Hydrochloride
60 mg TabletAlu/Alu Blister x 10's (Box of 30's, 60's and 100's)
RxVAT-exempt
Coral Laboratories Ltd.India
Despina Pharma Inc.
DRP-19115
Oct 29, 2031
Dilzep 90Diltiazem
90 mg Film-Coated TabletAlu Alu Blister Pack x 10's (Box of 30's and 60's)
RxVAT-exempt
Coral Laboratories Ltd.India
Despina Pharma, Inc.
DRP-14334
Aug 24, 2028
ForzemDiltiazem Hydrochloride
30 mg Film-Coated TabletBlister pack x 10's (Box of 100's)
RxVAT-exempt
Lloyd Laboratories, Inc.Philippines
TGP Pharma, Inc.Trader: D.B. Manix International, Inc.
DRP-871-02
Jul 14, 2031
Khrizdil 30Diltiazem Hydrochloride
30 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Merit Organics Ltd.India
Khriz Pharma Trading Inc.
DR-XY49817
Oct 12, 2031
Khrizdil 60Diltiazem Hydrochloride
60 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Merit Organics Ltd.India
Khriz Pharma Trading, Inc.
DR-XY49818
Oct 12, 2031
NoneDiltiazem Hydrochloride
60 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Centurion Remedies Pvt. Ltd.India
Watsons Personal Care Stores (Philippines), Inc.Importer: Philgen Pharmaceuticals Inc.
DRP-2512-01
Oct 16, 2031
NovoptinDiltiazem Hydrochloride
30 mg TabletAlu/Clear PVC Blister Pack x 20’s (Box of 100's)
RxVAT-exempt
San Marino Laboratories CorporationPhilippines
—
DRP-11766
Apr 29, 2031
NovoptinDiltiazem Hydrochloride
60 mg TabletAlu/Clear PVC Blister Pack x 10’s (Box of 100’s)
RxVAT-exempt
San Marino Laboratories CorporationPhilippines
—
DRP-6605
Jun 2, 2031
ZemdilDiltiazem Hydrochloride
30 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Centurion Remedies Pvt. Ltd.India
Philgen Pharmaceuticals Inc.
DRP-2656
Dec 23, 2030
ZemdilDiltiazem Hydrochloride
60 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's)
RxVAT-exempt
Centurion Remedies Pvt. Ltd.India
TGP Pharma Inc.Importer: Philhen Pharmaceuticals Inc.
DRP-2512
Oct 5, 2030

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Warnings/Precautions

Warnings and precautions (US label) US FDA label

WARNINGS Cardiac Conduction: CARDIZEM prolongs AV node refractory periods without significantly prolonging sinus node recovery time, except in patients with sick sinus syndrome. This effect may rarely result in abnormally slow heart rates (particularly in patients with sick sinus syndrome) or second- or third-degree AV block (six of 1243 patients for 0.48%).

Concomitant use of diltiazem with beta-blockers or digitalis may result in additive effects on cardiac conduction. A patient with Prinzmetal’s angina developed periods of asystole (2 to 5 seconds) after a single dose of 60 mg of diltiazem (see ADVERSE REACTIONS). Congestive Heart Failure: Although diltiazem has a negative inotropic effect in isolated animal tissue preparations, hemodynamic studies in humans with normal ventricular function have not shown a reduction in cardiac index nor consistent negative effects on contractility (dP/dt).

Experience with the use of CARDIZEM alone or in combination with beta-blockers in patients with impaired ventricular function is very limited. Caution should be exercised when using the drug in such patients. Hypotension: Decreases in blood pressure associated with CARDIZEM therapy may occasionally result in symptomatic hypotension.

Acute Hepatic Injury: In rare instances, significant elevations in enzymes such as alkaline phosphatase, LDH, SGOT, SGPT, and other phenomena consistent with acute hepatic injury have been noted. These reactions have been reversible upon discontinuation of drug therapy. The relationship to CARDIZEM is uncertain in most cases, but probable in some (see PRECAUTIONS).

Drug interactions

Drug interactions (US label) US FDA label

Drug Interactions Due to the potential for additive effects, caution and careful titration are warranted in patients receiving CARDIZEM concomitantly with any agents known to affect cardiac contractility and/or conduction (see WARNINGS). Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using beta-blockers or digitalis concomitantly with CARDIZEM (see WARNINGS).

Diltiazem is both a substrate and an inhibitor of the Pg-p and cytochrome P450 3A4 enzyme system which may affect exposure to diltiazem and concomitant drugs metabolized by those pathways. Patients with renal and/or hepatic impairment may be particularly at risk of exposure changes. Anesthetics: The depression of cardiac contractility, conductivity, and automaticity, as well as the vascular dilation associated with anesthetics, may be potentiated by calcium channel blockers.

When used concomitantly, anesthetics and calcium blockers should be titrated carefully. Benzodiazepines: Studies showed that diltiazem increased the AUC of midazolam and triazolam by 3- to 4-fold and the C max by 2-fold, compared to placebo. The elimination half-life of midazolam and triazolam also increased (1.5- to 2.5-fold) during coadministration with diltiazem.

These pharmacokinetic effects seen during diltiazem coadministration can result in increased clinical effects (e.g., prolonged sedation) of both midazolam and triazolam. Beta-blockers: Controlled and uncontrolled domestic studies suggest that concomitant use of CARDIZEM and beta-blockers is usually well tolerated. Available data are not sufficient, however, to predict the effects of concomitant treatment, particularly in patients with left ventricular dysfunction or cardiac conduction abnormalities.

Administration of CARDIZEM (diltiazem hydrochloride) concomitantly with propranolol in five normal volunteers resulted in increased propranolol levels in all subjects, and bioavailability of propranolol was increased approximately 50%. In vitro, propranolol appears to be displaced from its binding sites by diltiazem. If combination therapy is initiated or withdrawn in conjunction with propranolol, an adjustment in the propranolol dose may be warranted (see WARNINGS).

Buspirone: In nine healthy subjects, diltiazem significantly increased the mean buspirone AUC 5.5-fold and C max 4.1-fold compared to placebo. The T 1/2 and T max of buspirone were not significantly affected by diltiazem. Enhanced effects and increased toxicity of buspirone may be possible during concomitant administration with diltiazem.

Subsequent dose adjustments may be necessary during coadministration and should be based on clinical assessment. Carbamazepine: Concomitant administration of diltiazem with carbamazepine has been reported to result in elevated serum levels of carbamazepine (40% to 72% increase) resulting in toxicity in some cases. Patients receiving these drugs concurrently should be monitored for a potential drug interaction.

Cimetidine: A study in six healthy volunteers has shown a significant increase in peak diltiazem plasma levels (58%) and area-under-the-curve (53%) after a 1-week course of cimetidine at 1200 mg per day and a single dose of diltiazem 60 mg. Ranitidine produced smaller, nonsignificant increases. The effect may be mediated by cimetidine’s known inhibition of hepatic cytochrome P450, the enzyme system responsible for the first-pass metabolism of diltiazem.

Patients currently receiving diltiazem therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with cimetidine. An adjustment in the diltiazem dose may be warranted. Clonidine: Sinus bradycardia resulting in hospitalization and pacemaker insertion has been reported in association with the use of clonidine concurrently with diltiazem.

Monitor heart rate in patients receiving concomitant diltiazem and clonidine. Cyclosporine: A pharmacokinetic interaction between diltiazem and cyclosporine has been observed during studies involving renal and cardiac transplant patients. In renal and cardiac transplant recipients, a reduction of cyclosporine trough dose ranging from 15% to 48% was necessary to maintain concentrations similar to those seen prior to the addition of diltiazem.

If these agents are to be administered concurrently, cyclosporine concentrations should be monitored, especially when diltiazem therapy is initiated, adjusted, or discontinued. The effect of cyclosporine on diltiazem plasma concentrations has not been evaluated. Digitalis: Administration of CARDIZEM with digoxin in 24 healthy male subjects increased plasma digoxin concentrations approximately 20%.

Another investigator found no increase in digoxin levels in 12 patients with coronary artery disease. Since there have been conflicting results regarding the effect of digoxin levels, it is recommended that digoxin levels be monitored when initiating, adjusting, and discontinuing CARDIZEM therapy to avoid possible over- or under-digitalization (see WARNINGS).

Ivabradine: Concurrent use of diltiazem increases exposure to ivabradine and may exacerbate bradycardia and conduction disturbances. Avoid concomitant use of ivabradine and diltiazem. Quinidine: Diltiazem significantly increases the AUC (0→∞) of quinidine by 51%, T 1/2 by 36%, and decreases its CL oral by 33%. Monitoring for quinidine adverse effects may be warranted and the dose adjusted accordingly.

Rifampin: Coadministration of rifampin with diltiazem lowered the diltiazem plasma concentrations to undetectable levels. Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered. Statins: Diltiazem is an inhibitor of CYP3A4 and has been shown to increase significantly the AUC of some statins.

The risk of myopathy and rhabdomyolysis with statins metabolized by CYP3A4 may be increased with concomitant use of diltiazem. When possible, use a non-CYP3A4-metabolized statin together with diltiazem; otherwise, dose adjustments for both diltiazem and the statin should be considered along with close monitoring for signs and symptoms of any statin-related adverse events.

In a healthy volunteer crossover study (N=10), coadministration of a single 20 mg dose of simvastatin at the end of a 14-day regimen with 120 mg BID diltiazem SR resulted in a 5-fold increase in mean simvastatin AUC versus simvastatin alone. Subjects with increased average steady-state exposures of diltiazem showed a greater fold increase in simvastatin exposure.

Computer-based simulations showed that at a daily dose of 480 mg of diltiazem, an 8- to 9-fold mean increase in simvastatin AUC can be expected. If coadministration of simvastatin with diltiazem is required, limit the daily doses of simvastatin to 10 mg and diltiazem to 240 mg. In a ten-subject randomized, open label, 4-way crossover study, coadministration of diltiazem (120 mg BID diltiazem SR for 2 weeks) with a single 20 mg dose of lovastatin resulted in 3- to 4-fold increase in mean lovastatin AUC and C max versus lovastatin alone.

In the same study, there was no significant change in 20 mg single dose pravastatin AUC and C max during diltiazem coadministration. Diltiazem plasma levels were not significantly affected by lovastatin or pravastatin.

Metabolism and transporters (CYP, P-gp, OATP; US label) US FDA label

Coadministration of diltiazem with rifampin or any known CYP3A4 inducer should be avoided when possible, and alternative therapy considered.

Statins: Diltiazem is an inhibitor of CYP3A4 and has been shown to increase significantly the AUC of some statins.

The risk of myopathy and rhabdomyolysis with statins metabolized by CYP3A4 may be increased with concomitant use of diltiazem.

When possible, use a non-CYP3A4-metabolized statin together with diltiazem; otherwise, dose adjustments for both diltiazem and the statin should be considered along with close monitoring for signs and symptoms of any statin-related adverse events.

Adverse reactions

Adverse reactions (US label) US FDA label

ADVERSE REACTIONS Serious adverse reactions have been rare in studies carried out to date, but it should be recognized that patients with impaired ventricular function and cardiac conduction abnormalities usually have been excluded. In domestic placebo-controlled angina trials, the incidence of adverse reactions reported during CARDIZEM therapy was not greater than that reported during placebo therapy.

The following represent occurrences observed in clinical studies of angina patients. In many cases, the relationship to CARDIZEM has not been established. The most common occurrences from these studies, as well as their frequency of presentation, are edema (2.4%), headache (2.1%), nausea (1.9%), dizziness (1.5%), rash (1.3%), and asthenia (1.2%).

In addition, the following events were reported infrequently (less than 1%): Cardiovascular: Angina, arrhythmia, AV block (first-degree), AV block (second- or third-degree – see WARNINGS, Cardiac Conduction), bradycardia, bundle branch block, congestive heart failure, ECG abnormality, flushing, hypotension, palpitations, syncope, tachycardia, ventricular extrasystoles Nervous System: Abnormal dreams, amnesia, depression, gait abnormality, hallucinations, insomnia, nervousness, paresthesia, personality change, somnolence, tremor Gastrointestinal: Anorexia, constipation, diarrhea, dysgeusia, dyspepsia, mild elevations of alkaline phosphatase, SGOT, SGPT, and LDH (see WARNINGS, Acute Hepatic Injury), thirst, vomiting, weight increase. Dermatological: Petechiae, photosensitivity, pruritus, urticaria Other: Amblyopia, CPK elevation, dry mouth, dyspnea, epistaxis, eye irritation, hyperglycemia, hyperuricemia, impotence, muscle cramps, nasal congestion, nocturia, osteoarticular pain, polyuria, sexual difficulties, tinnitus The following postmarketing events have been reported infrequently in patients receiving CARDIZEM: acute generalized exanthematous pustulosis, allergic reactions, alopecia, angioedema (including facial or periorbital edema), asystole, erythema multiforme (including Stevens-Johnson syndrome, toxic epidermal necrolysis), extrapyramidal symptoms, gingival hyperplasia, hemolytic anemia, increased bleeding time, leukopenia, photosensitivity (including lichenoid keratosis and hyperpigmentation at sun-exposed skin areas), purpura, retinopathy, myopathy, and thrombocytopenia.

There have been observed cases of a generalized rash, some characterized as leukocytoclastic vasculitis. In addition, events such as myocardial infarction have been observed, which are not readily distinguishable from the natural history of the disease in these patients. A definitive cause and effect relationship between these events and CARDIZEM therapy cannot yet be established.

Exfoliative dermatitis (proven by rechallenge) has also been reported. To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Pregnancy considerations

Pregnancy (US label) US FDA label

Pregnancy Reproduction studies have been conducted in mice, rats, and rabbits. Administration of doses ranging from five to ten times greater (on a mg/kg basis) than the daily recommended therapeutic dose has resulted in embryo and fetal lethality. These doses, in some studies, have been reported to cause skeletal abnormalities.

In the perinatal/postnatal studies, there was some reduction in early individual pup weights and survival rates. There was an increased incidence of stillbirths at doses of 20 times the human dose or greater. There are no well-controlled studies in pregnant women; therefore, use CARDIZEM in pregnant women only if the potential benefit justifies the potential risk to the fetus.

Breastfeeding considerations

Lactation (US label) US FDA label

Nursing Mothers Diltiazem is excreted in human milk. One report suggests that concentrations in breast milk may approximate serum levels. If use of CARDIZEM is deemed essential, an alternative method of infant feeding should be instituted.

Mechanism of action

Mechanisms of Action Although precise mechanisms of its antianginal actions are still being delineated, CARDIZEM is believed to act in the following ways: Angina Due to Coronary Artery Spasm: CARDIZEM has been shown to be a potent dilator of coronary arteries both epicardial and subendocardial. Spontaneous and ergonovine-induced coronary artery spasms are inhibited by CARDIZEM.

Exertional Angina: CARDIZEM has been shown to produce increases in exercise tolerance, probably due to its ability to reduce myocardial oxygen demand. This is accomplished via reductions in heart rate and systemic blood pressure at submaximal and maximal exercise workloads. In animal models, diltiazem interferes with the slow inward (depolarizing) current in excitable tissue.

It causes excitation-contraction uncoupling in various myocardial tissues without changes in the configuration of the action potential. Diltiazem produces relaxation of coronary vascular smooth muscle and dilation of both large and small coronary arteries at drug levels which cause little or no negative inotropic effect.

The resultant increases in coronary blood flow (epicardial and subendocardial) occur in ischemic and nonischemic models and are accompanied by dose-dependent decreases in systemic blood pressure and decreases in peripheral resistance.

US FDA label

Pharmacokinetics

Half-life and elimination (verbatim, US label)

The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.

A study that compared patients with normal hepatic function to patients with cirrhosis found an increase in half-life and a 69% increase in AUC (area-under-the-plasma concentration vs. time curve) in the hepatically impaired patients.

Pharmacokinetics (US label) US FDA label

Pharmacokinetics and Metabolism Diltiazem is well absorbed from the gastrointestinal tract and is subject to an extensive first-pass effect, giving an absolute bioavailability (compared to intravenous dosing) of about 40%. CARDIZEM undergoes extensive metabolism in which 2% to 4% of the unchanged drug appears in the urine.

In vitro binding studies show CARDIZEM is 70% to 80% bound to plasma proteins. Competitive in vitro ligand binding studies have also shown CARDIZEM binding is not altered by therapeutic concentrations of digoxin, hydrochlorothiazide, phenylbutazone, propranolol, salicylic acid, or warfarin. The plasma elimination half-life following single or multiple drug administration is approximately 3.0 to 4.5 hours.

Desacetyl diltiazem is also present in the plasma at levels of 10% to 20% of the parent drug and is 25% to 50% as potent as a coronary vasodilator as diltiazem. Minimum therapeutic plasma levels of CARDIZEM appear to be in the range of 50 to 200 ng/mL. There is a departure from linearity when dose strengths are increased.

A study that compared patients with normal hepatic function to patients with cirrhosis found an increase in half-life and a 69% increase in AUC (area-under-the-plasma concentration vs. time curve) in the hepatically impaired patients. A single study in nine patients with severely impaired renal functions showed no difference in the pharmacokinetic profile of diltiazem as compared to patients with normal renal function.

CARDIZEM Tablets: Diltiazem is absorbed from the tablet formulation to about 98% of a reference solution. Single oral doses of 30 to 120 mg of CARDIZEM tablets result in detectable plasma levels within 30 to 60 minutes and peak plasma levels 2 to 4 hours after drug administration. As the dose of CARDIZEM tablets is increased from a daily dose of 120 mg (30 mg QID) to 240 mg (60 mg QID) daily, there is an increase in area-under-the-curve of 2.3 times.

When the dose is increased from 240 mg to 360 mg daily, there is an increase in area-under-the-curve of 1.8 times.

Formulary and pricing (Philippines)

Government price references

PreparationPrice (PHP)UnitType
Diltiazem 60 mg Tablet₱3.10–₱36.99Reference ₱12.00per tabletDPRI procurement range
60 mg (as hydrochloride) modified release capsule₱15.75per capsulePhilHealth GAMOT fixed fee
60 mg (as hydrochloride) tablet₱21.00per tabletPhilHealth GAMOT fixed fee
120 mg (as hydrochloride) modified release capsule₱96.50per capsulePhilHealth GAMOT fixed fee
120 mg (as hydrochloride) modified release tablet₱96.50per tabletPhilHealth GAMOT fixed fee
180 mg (as hydrochloride) modified release capsule₱115.75per capsulePhilHealth GAMOT fixed fee
180 mg (as hydrochloride) modified release tablet₱115.75per tabletPhilHealth GAMOT fixed fee

PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)

These are government procurement and reimbursement references, not retail prices. Sources:

Formulary and coverage

Philippine National FormularyListed as Diltiazem (as hydrochloride)
PNF listingOral: 60 mg tablet
PNF listingOral: 60 mg, 120 mg, 180 mg and 240 mg MR capsule (as hydrochloride)
PNF listingOral: 120 mg and 180 mg MR tablet (as hydrochloride)
PhilHealth GAMOTYes (listed since July 28, 2025)

Sources:

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. U.S. Food and Drug Administration. Cardizem · Bausch Health US LLC [US FDA-approved label, version 20, April 30, 2025]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f3e7ecef-f360-4987-a4f5-933214130ab2
  2. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
  3. PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
  4. PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  5. PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
  6. DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .